PDF(Pubmed)
Abstract：
UNASSIGNED: Although long-term survival in patients with metastatic colorectal cancer (mCRC) is limited, treatments for third-line and later treatment are now recommended. We describe a patient who achieved long-term survival when they received third-line treatment with trifluridine/tipiracil (FTD/TPI).
UNASSIGNED: The woman who was 52 years old at diagnosis of adenocarcinoma of the right colon (T3/N0/M1) with metastases to the lung, liver, ovary, and other soft tissues received first-line fluoropyrimidine-based chemotherapy (FOLFOX/FOLFIRI plus bevacizumab) intermittently for approximately 8.5 years with generally stable disease, and second-line FOLFIRI plus radiotherapy. After progression on second-line therapy, the patient initiated treatment with FTD/TPI 35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle. She received a total of 38 cycles of FTD/TPI over a period of 34 months achieving a partial response, maintained performance status, and improved quality of life. Neutropenia was successfully managed with FTD/TPI dose delays or reductions.
UNASSIGNED: This heavily pre-treated patient with mCRC demonstrated impressive long-term survival and maintenance of good quality of life with FTD/TPI treatment.
UNASSIGNED: The woman who was 52 years old at diagnosis of adenocarcinoma of the right colon (T3/N0/M1) with metastases to the lung, liver, ovary, and other soft tissues received first-line fluoropyrimidine-based chemotherapy (FOLFOX/FOLFIRI plus bevacizumab) intermittently for approximately 8.5 years with generally stable disease, and second-line FOLFIRI plus radiotherapy. After progression on second-line therapy, the patient initiated treatment with FTD/TPI 35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle. She received a total of 38 cycles of FTD/TPI over a period of 34 months achieving a partial response, maintained performance status, and improved quality of life. Neutropenia was successfully managed with FTD/TPI dose delays or reductions.
UNASSIGNED: This heavily pre-treated patient with mCRC demonstrated impressive long-term survival and maintenance of good quality of life with FTD/TPI treatment.
摘要：
■尽管转移性结直肠癌（mCRC）患者的长期生存率有限，现在建议使用三线和后期治疗.我们描述了一名患者，当他们接受三氟尿苷/替吡草胺（FTD/TPI）的三线治疗时，他们获得了长期生存。
■诊断为右结肠腺癌（T3/N0/M1）并向肺转移的52岁女性，肝脏,子房,和其他软组织接受以氟嘧啶为基础的一线化疗（FOLFOX/FOLFIRI加贝伐单抗）间歇性约8.5年，疾病总体稳定，和二线FOLFIRI加放疗。在二线治疗进展后，患者在每个28天周期的第1-5天和第8-12天开始使用FTD/TPI35mg/m2每日2次治疗.在34个月的时间里，她总共收到了38个周期的FTD/TPI，实现了部分响应，保持的性能状态，提高了生活质量。中性粒细胞减少症通过FTD/TPI剂量延迟或减少成功治疗。
■这位经过大量预处理的mCRC患者在FTD/TPI治疗下表现出令人印象深刻的长期生存率和良好的生活质量。
■诊断为右结肠腺癌（T3/N0/M1）并向肺转移的52岁女性，肝脏,子房,和其他软组织接受以氟嘧啶为基础的一线化疗（FOLFOX/FOLFIRI加贝伐单抗）间歇性约8.5年，疾病总体稳定，和二线FOLFIRI加放疗。在二线治疗进展后，患者在每个28天周期的第1-5天和第8-12天开始使用FTD/TPI35mg/m2每日2次治疗.在34个月的时间里，她总共收到了38个周期的FTD/TPI，实现了部分响应，保持的性能状态，提高了生活质量。中性粒细胞减少症通过FTD/TPI剂量延迟或减少成功治疗。
■这位经过大量预处理的mCRC患者在FTD/TPI治疗下表现出令人印象深刻的长期生存率和良好的生活质量。
